Posted by Michael Wonder on 07 Oct 2021
Joint statement: supply allocations of intravenous tocilizumab (Actemra) during serious shortage
7 October 2021 - Roche, the sponsor of tocilizumab (Actemra), notified the TGA of shortages of multiple presentations of tocilizumab products due to a significant increase in global demand for tocilizumab arising from its use in treating critically ill COVID-19 patients.
Global supply is now extremely limited and patient level shortages are expected until early 2022.
